Literature DB >> 29657551

Recombinant-follicle stimulating hormone is more effective than urinary human menopausal gonadotropin in ovarian hyperstimulation for assisted reproductive technology treatment.

Koji Nakagawa1, Shirei Ohgi1, Rieko Kojima1, Kana Sugawara1, Takashi Horikawa1, Megumu Ito1, Minoaru Irahara2, Hidekazu Saito1.   

Abstract

Aim:  The aim of the present study was to establish a standard protocol for ovarian stimulation with gonadotropin-releasing hormone analog (GnRH-a) long protocol using recombinant-follicle stimulating hormone (rec-FSH) preparations for assisted reproductive technology (ART) treatment.
Methods:   In 86 patients who underwent ovarian stimulation with GnRH-a long protocol for ART treatment, 53 were stimulated by rec-FSH preparations (rec-FSH group) and the others were stimulated by urinary-hMG (u-hMG group) preparations. The subjects were randomly assigned to either of these preparations. Hormonal profiles, total doses of gonadotropins, duration of stimulation and ART results were compared in both groups.
Results:   The duration of stimulation was similar in both groups (9.2 ± 0.3 days and 9.2 ± 0.2 days, respectively). The total doses of gonadotropin in the rec-FSH group (1505.3 ± 29.2 IU) was significantly lower than those in the u-hMG group (2130.3 ± 54.6 IU, P < 0.0001). The FSH and LH values on the day of human chorionic gonadotropin (hCG) administration in the rec-FSH group were significantly lower than those in the u-hMG group. Pregnancy rates were 31.3% in the rec-FSH group and 33.3% in the u-hMG group, respectively. Conclusions:  The present study showed that rec-FSH preparations were more potent than conventional u-hMG preparations and the protocol of the present study with rec-FSH was a new ovarian stimulation protocol with GnRH-a long protocol. (Reprod Med Biol 2007; 6: 27-32).

Entities:  

Keywords:  assisted reproductive technology; ovarian stimulation; recombinant‐follicle stimulating hormone; urinary hMG

Year:  2007        PMID: 29657551      PMCID: PMC5891765          DOI: 10.1111/j.1447-0578.2007.00161.x

Source DB:  PubMed          Journal:  Reprod Med Biol        ISSN: 1445-5781


  11 in total

1.  Sandwich configuration of type I collagen suppresses progesterone production in primary cultured porcine granulosa cells by reducing gene expression of cytochrome P450 cholesterol side-chain cleavage enzyme.

Authors:  X Wang; K Otsu; H Saito; M Hiroi; K Ishikawa
Journal:  Arch Biochem Biophys       Date:  2000-04-01       Impact factor: 4.013

2.  A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers.

Authors:  G Voortman; B M Mannaerts; J A Huisman
Journal:  Fertil Steril       Date:  2000-06       Impact factor: 7.329

Review 3.  Optimal stimulation protocols for in vitro fertilization.

Authors:  Suheil J Muasher; Rony T Abdallah; Ziad R Hubayter
Journal:  Fertil Steril       Date:  2006-06-06       Impact factor: 7.329

4.  Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone.

Authors:  B Mannaerts; R de Leeuw; J Geelen; A Van Ravestein; P Van Wezenbeek; A Schuurs; H Kloosterboer
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

5.  Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.

Authors:  B Hedon; H J Out; J N Hugues; B Camier; J Cohen; P Lopes; J R Zorn; B van der Heijden; H J Coelingh Bennink
Journal:  Hum Reprod       Date:  1995-12       Impact factor: 6.918

6.  HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial.

Authors:  E H Ng; E Y Lau; W S Yeung; P C Ho
Journal:  Hum Reprod       Date:  2001-02       Impact factor: 6.918

Review 7.  Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon).

Authors:  W Olijve; W de Boer; J W Mulders; P M van Wezenbeek
Journal:  Mol Hum Reprod       Date:  1996-05       Impact factor: 4.025

8.  Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.

Authors:  P Devroey; B Mannaerts; J Smitz; H Coelingh Bennink; A Van Steirteghem
Journal:  Hum Reprod       Date:  1994-06       Impact factor: 6.918

Review 9.  Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles.

Authors:  M Van Wely; L G Westergaard; P M M Bossuyt; F Van der Veen
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial.

Authors: 
Journal:  Fertil Steril       Date:  2002-09       Impact factor: 7.329

View more
  1 in total

1.  The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH.

Authors:  Koji Nakagawa; Shirei Ohgi; Akira Nakashima; Takashi Horikawa; Rikikazu Sugiyama; Hidekazu Saito
Journal:  J Assist Reprod Genet       Date:  2008-08-28       Impact factor: 3.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.